Cover Image

PAPERBACK
$43.50



View/Hide Left Panel

TABLE 7.1 The Basis for Estimating the Annual Number of New Potential Vaccinees and the Delay in Vaccination Benefits

Pathogen (Target Population)

Type of Vaccine

Individuals Entering Target Populationa

Delay in Vaccination Benefits

Dengue virus

(Infants and children in endemic areas; travelers to endemic areas)

Attenuated live vector virus containing gene for broadly cross-reacting protective antigen

Birth cohort in endemic areas: 48 million

Probable age of vaccination

(<1 year) to peak of DHF/DSSb (6 years), i.e., approx. 5 years

Vaccinate to peak age of dengue fever (adolescents and adults)

Escherichia coli

(enterotoxigenic)

(Infants<6 months)

A combination of purified colonization factor antigens and possibly other antigens

Birth cohort: 115.1 million

Probable age of vaccination

(<1 year) to peak age of disease (1–2 years), i.e., approx. 1 year

Genetically engineered attenuated strains

Hemophilus influenzae type b

(Infants)

Conjugated polysaccharide

Birth cohort: 115.1 million

Probable age of vaccination

(<1 year) to peak of serious disease (2–3 years), i.e., approx. 2 years

Hepatitis A virus

(Susceptibles of all ages; routine for preschool children)

Attenuated live virus

Birth cohort: 115.1 million

Probable age of vaccination

(<1 year) to peak age of disease in LTDCs (2–4), i.e., approx. 2 years

Polypeptide recombinant vaccine produced in yeast

Hepatitis B virus

(Areas with high perinatal infection: all infants at birth (if possible). Other areas: all infants, simultaneous with other vaccinations, at earliest possible age)

Polypeptide produced by recombinant DNA technology

Birth cohort: 115.1 million

Probable age of vaccination

(<1 year) to mid-point between peak of acute disease (10 years) and serious chronic illness (35–40 years), i.e., approx. 30 years

Japanese encephalitis virus

(Children in epidemic and endemic areas; foreign visitors to epidemic regions)

Inactivated virus produced in cell culture

Birth cohort in endemic/ epidemic areas: 64.8 million

Probable age of vaccination

(<1 year) to peak age of disease (approx. age 8), i.e. approx. 7 years

Mycobacterium leprae

(Immunoprophylactic: all children in endemic areas. Immunotherapeutic: all recently infected individuals)

Armadillo-derived M. leprae

Immunoprophylactic—birth cohort in endemic areas: 44.8 million

Immunotherapeutic—incidence approx. 1.5 million

6 years, based on estimated incubation period



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement